236 related articles for article (PubMed ID: 24857058)
1. Role of hormones in cancer prevention.
Vogel VG
Am Soc Clin Oncol Educ Book; 2014; ():34-40. PubMed ID: 24857058
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
3. The endocrine prevention of breast cancer.
Howell A
Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors and breast cancer prevention.
Litton JK; Arun BK; Brown PH; Hortobagyi GN
Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
[TBL] [Abstract][Full Text] [Related]
5. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
6. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
8. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
10. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
11. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
13. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
Lo SS; Vogel VG
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):97-111. PubMed ID: 14687600
[TBL] [Abstract][Full Text] [Related]
14. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
15. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
16. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
17. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
18. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
19. Exemestane for breast-cancer prevention in postmenopausal women.
Goss PE; Ingle JN; Alés-Martínez JE; Cheung AM; Chlebowski RT; Wactawski-Wende J; McTiernan A; Robbins J; Johnson KC; Martin LW; Winquist E; Sarto GE; Garber JE; Fabian CJ; Pujol P; Maunsell E; Farmer P; Gelmon KA; Tu D; Richardson H;
N Engl J Med; 2011 Jun; 364(25):2381-91. PubMed ID: 21639806
[TBL] [Abstract][Full Text] [Related]
20. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]